PARP inhibitors have the potential to enhance immunotherapy via promoting tumor immunogenicity by cGAS-STING pathway.28 But PARPi-based immunotherapies did not function for HRD patients as efficiently as expected, which indicated the existence of intrinsic resistant factors in HRD tumor to impede the enhancement of immunogenicity by PARPi. This evidence concerns the gene CGAS and hypoparathyroidism-retardation-dysmorphism syndrome.